Rectal cancer

Overview

Rectal cancer is a malignant disease arising from the epithelial lining of the rectum—the final 12 to 15 centimeters (approximately 5 to 6 inches) of the large intestine, terminating at the anal canal. While often grouped with colon cancer under the umbrella term “colorectal cancer,” rectal cancer is a distinct clinical entity. Its unique pelvic anatomy—confined within a narrow bony pelvis, surrounded by critical nerves, blood vessels, and genitourinary organs—dictates specific diagnostic approaches, staging criteria, and multimodal treatment strategies that differ significantly from those for colon cancer.

Globally, colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death. Rectal cancer accounts for approximately 30% of all colorectal cancer cases. The incidence is rising notably in adults under 50 (early-onset colorectal cancer), prompting guideline changes for screening initiation.

Key Distinction: Unlike the colon, the rectum lacks a serosal layer (a smooth outer covering) on its anterior and lower surfaces. This anatomical feature allows tumors to penetrate directly into surrounding pelvic structures (prostate, seminal vesicles, vagina, uterus, bladder, sacrum) at an earlier stage, increasing the risk of local recurrence and necessitating neoadjuvant (pre-operative) therapy more frequently than in colon cancer.

Anatomy of the Rectum: Why Location Matters

Understanding rectal anatomy is essential for understanding staging and surgery.

The Mesorectum: A fatty envelope surrounding the rectum containing lymph nodes, blood vessels, and autonomic nerves (hypogastric plexus, pelvic splanchnic nerves). Total Mesorectal Excision (TME)—sharp dissection along the embryological fascial plane of the mesorectum—is the gold standard surgical technique to minimize local recurrence and preserve urinary/sexual function.

Risk Factors and Etiology

Rectal cancer develops through a complex interplay of genetic susceptibility and environmental exposures. The majority (70–80%) are sporadic; 20–30% have a familial component; 5–10% are due to defined hereditary syndromes.

Modifiable Risk Factors

• Diet: High intake of red meat (>500g/week) and processed meats (Group 1 carcinogen, WHO/IARC). Low dietary fiber, low fruit/vegetable intake.
• Obesity & Metabolic Syndrome: Central adiposity (visceral fat) correlates with insulin resistance, chronic inflammation (high IL-6, TNF-α), and elevated IGF-1, promoting tumorigenesis. BMI >30 increases risk by ~30–50%.
• Physical Inactivity: Independent risk factor; regular vigorous activity reduces risk by 20–25%.
• Alcohol: Dose-dependent relationship; ≥2 drinks/day significantly increases risk (acetaldehyde toxicity, folate antagonism).
• Tobacco Smoking: Long-term smoking (>20 pack-years) increases risk and is linked to specific molecular subtypes (e.g., BRAF mutation, CpG Island Methylator Phenotype – CIMP).
• Type 2 Diabetes Mellitus: Independent risk factor (hyperinsulinemia).

Non-Modifiable Risk Factors

• Age: Median diagnosis age 63; steep rise after 50. Incidence <50 rising ~2% annually.
• Personal History: Prior adenomatous polyps (especially >1cm, villous histology, high-grade dysplasia), prior CRC, history of ovarian/endometrial/breast cancer.
• Inflammatory Bowel Disease (IBD): Ulcerative Colitis (UC) and Crohn’s colitis. Risk correlates with duration (>8–10 years), extent (pancolitis > left-sided), and severity of inflammation. Primary Sclerosing Cholangitis (PSC) doubles the risk in UC patients.
• Family History: One first-degree relative (FDR) diagnosed <60 years, or two FDRs at any age → 2x to 4x risk.
• Hereditary Syndromes:
• Lynch Syndrome (HNPCC): Mismatch repair (MMR) gene mutations (MLH1, MSH2, MSH6, PMS2, EPCAM). Lifetime CRC risk 40–80%; early onset (avg 44y); right-sided predominance but rectal occurs. Tumors are MSI-High (MSI-H).
• Familial Adenomatous Polyposis (FAP): APC gene mutation. Hundreds-thousands of polyps. Prophylactic colectomy usually indicated in teens/20s.
• MUTYH-Associated Polyposis (MAP): Autosomal recessive. Attenuated polyposis.
• Hamartomatous Polyposis Syndromes: Peutz-Jeghers (STK11), Juvenile Polyposis (SMAD4/BMPR1A).

Molecular Pathways: The Biology Behind the Disease

Understanding molecular subtypes guides prognosis and therapy (especially immunotherapy).

Clinical Pearl:** *Universal molecular testing (MSI/MMR, RAS, BRAF, HER2, NTRK) is now standard of care at diagnosis of metastatic disease (Stage IV) and for all newly diagnosed rectal cancers to screen for Lynch Syndrome.

How Does It Look: Endoscopic, Radiologic, and Gross Pathology Appearance

This section details the visual phenotype of rectal cancer across diagnostic modalities. Recognizing these features is critical for early detection, accurate staging, and treatment planning.

1. Endoscopic Appearance (Colonoscopy / Flexible Sigmoidoscopy)

The “look” of the tumor dictates the biopsy strategy and raises suspicion for specific histologic subtypes.

Endoscopic Ultrasound (EUS) “Look”:

• Layered Architecture: Normal rectal wall = 5 alternating hyperechoic/hypoechoic layers.
• Layer 1 (Superficial mucosa): Hyperechoic.
• Layer 2 (Deep mucosa/Lamina propria): Hypoechoic.
• Layer 3 (Submucosa): Hyperechoic (Critical landmark).
• Layer 4 (Muscularis Propria): Hypoechoic.
• Layer 5 (Subserosa/Perirectal fat): Hyperechoic.
• Tumor Appearance: Hypoechoic mass disrupting layers.
• T1: Confined to Layers 1–2.
• T2: Invades Layer 4 (Muscularis Propria).
• T3: Breaches Layer 4, extends into Layer 5 (Perirectal fat/mesorectum).
• T4: Invades adjacent organs (prostate, vagina, bladder wall – seen as loss of fat plane).

2. Radiologic Appearance (MRI – Gold Standard for Local Staging)

High-Resolution Rectal MRI (with phased-array coil, no endorectal balloon preferred) is the cornerstone of staging. It visualizes the Mesorectal Fascia (MRF) – the surgical resection plane.

Special MRI Signs:

• “Napkin Ring” Sign: Circumferential thickening with shouldered edges on T2-weighted images → Constricting annular carcinoma.
• EMVI (Extramural Venous Invasion): Serpentine/tubular signal intensity projections from tumor into perirectal veins. Graded 0–4. Grade 2–4 = Positive EMVI → Indicates need for intensified systemic therapy.
• mrEMVI vs. hrEMVI: MRI-detected vs. Histology-detected. MRI has high specificity (~95%) but moderate sensitivity (~60-70%).

3. Gross Pathology Appearance (Surgical Specimen)

After neoadjuvant therapy (if given), the specimen is assessed for Tumor Regression Grade (TRG).

• Pre-treatment (Biopsy/Untreated Resection):
• Adenocarcinoma (NOS): Firm, gray-white, gritty mass. Ulcerated surface, necrotic center. Infiltrates wall.
• Mucinous Adenocarcinoma (>50% extracellular mucin): Gelatinous, mucoid, “colloid” appearance. Strips of tumor floating in mucin pools.
• Signet Ring Cell Carcinoma (>50% signet cells): Diffuse wall thickening (linitis plastica), often no discrete mass. Mucosa may look normal.
• Medullary Carcinoma: Soft, fleshy, bulky tumor with pushing borders, heavy lymphocytic infiltrate (TILs). Strongly associated with MSI-H/dMMR.
• Post-Neoadjuvant (TRG Assessment – e.g., Ryan/Dworak or CAP):
• Complete Response (ypT0N0 / TRG 0/1): No viable tumor cells. Only fibrosis, acellular mucin pools, calcification, or foam cells (macrophages) in rectal wall/mesorectum. “Fibrotic scar” palpable.
• Near Complete (TRG 2): Rare scattered tumor cells in fibrosis.
• Partial Response (TRG 3): Residual tumor evident but with fibrosis.
• Poor/No Response (TRG 4/5): Viable tumor dominates, minimal fibrosis.

Symptoms: Clinical Presentation in Detail

Symptoms vary by tumor location (low vs. high), size, and complications (obstruction, perforation). Crucially, early rectal cancer (T1/T2) is often asymptomatic. This underscores the importance of screening.

1. Local / Rectal Symptoms (Most Common Presenting Complaints)

Hematochezia (Bright Red Blood Per Rectum – BRBPR)

• Character: Bright red or maroon blood. Coats stool surface, mixed with stool (not just on paper), or drips into toilet after defecation.
• Differentiation from Hemorrhoids:
• Hemorrhoids: Blood on toilet paper, dripping after stool, painless, associated with prolapse/itching. Blood is bright red, separate from stool.
• Cancer: Blood mixed into stool, darker red/maroon possible, associated with change in caliber, tenesmus, weight loss. Never assume rectal bleeding is hemorrhoids without endoscopic evaluation.
• Mechanism: Friable tumor surface ulcerates; stool trauma causes bleeding.

Change in Bowel Habits (The “Cardinal Symptom”)

• Narrowing of Stool Caliber (“Pencil-thin” / “Ribbon” stools): Caused by circumferential luminal narrowing (napkin ring tumor) in mid/low rectum. Highly specific for rectal cancer.
• Increased Frequency / Urgency: Tumor reduces rectal reservoir capacity (compliance). Rectal wall stiffness (desmoplastic reaction) impairs accommodation reflex.
• Diarrhea / Loose Stools: Large villous adenomas or carcinomas can secrete mucus/electrolytes (rarely causing hypokalemia). Bile acid malabsorption if ileum involved/resected.

Tenesmus (The “Hallmark” of Rectal Cancer)

• Definition: A painful, persistent, ineffective urge to defecate despite an empty rectum. “Feeling like you have to go, but nothing comes out.”
• Pathophysiology: Tumor invasion of the rectal wall and perirectal nerves (pelvic plexus) + inflammation stimulates stretch receptors and pain fibers. Low rectal tumors (<5-6 cm from verge) irritate the internal/external sphincter complex and levator ani.
• Significance: Highly suggestive of locally advanced (T3/T4) low rectal cancer. Distinguishes rectal from proximal colon cancer.

Mucus / Pus Discharge

• Profuse mucoid discharge suggests villous histology (villous adenoma or mucinous adenocarcinoma).
• Purulent discharge suggests superimposed infection, fistula formation (rare), or necrosis.

Pain (Perirectal / Sacral / Suprapubic)

• Early: Usually absent. Visceral pain (vague, midline, poorly localized) from distension.
• Late / Advanced: Sharp, severe, unilateral pelvic/sacral/perineal pain = Neural invasion (PNI – Perineural Invasion) or direct invasion of sacral plexus (S2-S4), obturator nerve, or parietal peritoneum. “Sciatica” or pudendal neuralgia presentation. Ominous sign (T4b).

2. Systemic / Constitutional Symptoms

3. Complications / Acute Presentations

• Large Bowel Obstruction (LBO):
• Presentation: Absolute constipation, abdominal distension, vomiting (late), tympanic abdomen, high-pitched bowel sounds.
• Rectal Specifics: Distal obstruction allows massive proximal dilation (cecum >10-12cm = perforation risk). Competent Ileocecal Valve → Closed-loop obstruction → Ischemia/Perforation. Incompetent Valve → Decompression into terminal ileum.
• Management: Emergency decompression (stent vs. surgery). Stenting often used as “Bridge to Surgery” after neoadjuvant therapy in left-sided/rectal cancer.
• Perforation:
• Free perforation (peritonitis, sepsis) vs. Contained abscess (pelvic sepsis, pain, fever).
• Usually requires emergency surgery (Hartmann’s procedure common).
• Fistula Formation (T4b Invasion):
• Rectovesical Fistula: Mucus/pneumaturia (air in urine), recurrent UTIs (Male: prostate invaded; Female: vagina/uterus invaded).
• Rectovaginal Fistula: Passage of flatus/feces per vagina.
• Rectocutaneous Fistula: Drainage through perineal/abdominal wall skin.

4. Metastatic Symptoms (Stage IV)

• Liver (Most common ~70%): RUQ pain, hepatomegaly, jaundice (late), elevated ALP/GGT/Bilirubin.
• Lungs (~30%): Cough, dyspnea, hemoptysis, pleural effusion.
• Peritoneum: Ascites, abdominal distension, ovarian metastases (Krukenberg tumor – signet ring histology).
• Bone / Brain: Rare (<5%), bone pain, fractures, neurological deficits.

5. Paraneoplastic Syndromes (Rare)

• Troussau’s Syndrome: Migratory superficial thrombophlebitis / Hypercoagulability (DVT/PE). Adenocarcinoma mucins activate Factor X.
• Acquired von Willebrand Syndrome: Adsorption of vWF onto tumor mucin.
• Dermatomyositis / Acanthosis Nigricans: Associated with GI adenocarcinomas.

Screening and Early Detection

Guidelines (Average Risk)

• Start Age: 45 years (USPSTF, ACS, ACG 2021/2022 update due to rising early-onset incidence).
• Modalities:
• Colonoscopy (Gold Standard): Every 10 years. Diagnostic + Therapeutic (polypectomy). Visualizes entire colon/rectum.
• FIT (Fecal Immunochemical Test): Annual. Detects globin (human hemoglobin). Specific for lower GI bleed. No dietary restrictions.
• mt-sDNA (Cologuard / FIT-DNA): Every 3 years. Detects hemoglobin + DNA methylation markers (NDRG4, BMP3) + KRAS mutations. Higher sensitivity for advanced adenomas/CRC than FIT, lower specificity (more false positives → colonoscopy needed).
• CT Colonography (Virtual Colonoscopy): Every 5 years. Requires prep. No sedation. Finds extracolonic findings (incidentalomas). Cannot biopsy.
• Flexible Sigmoidoscopy: Every 5 years (or q10y + annual FIT). Only sees distal 60cm. Misses proximal lesions. Less used now.

High-Risk / Surveillance Intervals

• IBD (UC/Crohn’s): Colonoscopy 8 yrs after pancolitis dx, 12-15 yrs after left-sided. Then q1-3yrs. Chromoendoscopy + targeted biopsies.
• Post-Polypectomy: Based on USMSTF 2020 guidelines (Table below).
• Lynch Syndrome: Colonoscopy q1-2yrs starting age 20-25 (or 2-5 yrs younger than earliest dx in family).
• FAP: Sigmoidoscopy/Colonoscopy annually from teens.

Table: Post-Polypectomy Surveillance Intervals (Simplified USMSTF 2020)

Diagnostic Workup: Step-by-Step

1. History & Physical: Digital Rectal Exam (DRE) Mandatory. Assesses: Tumor distance from anal verge, mobility (fixed vs. mobile), sphincter tone, perineal sensation, inguinal lymph nodes.
2. Endoscopy + Biopsy:

• Colonoscopy to cecum (rule out synchronous lesions ~3-5%).
• Multiple biopsies (≥6) for histology, MMR/MSI testing, KRAS/NRAS/BRAF/HER2/NTRK (if metastatic).
• Tattooing (India ink/Spot) proximal to tumor for surgical localization.

1. Staging Imaging:

• Pelvic MRI (High-Resolution, T2-weighted): Primary local staging tool. Assesses T-stage, MRF/CRM, EMVI, N-stage, Sphincter involvement.
• CT Chest/Abdomen/Pelvis (with IV contrast): Primary distant staging tool. Liver mets, lung nodules, nodal stations outside pelvis (para-aortic).
• PET-CT: Not routine for primary staging. Indicated for: Equivocal CT findings, recurrence workup, oligometastatic disease assessment for curative resection.
• Endorectal Ultrasound (EUS): Complementary for early T1/T2 (superior T accuracy), nodal assessment limited by shadowing. Used if MRI contraindicated or for early lesion ESD assessment.

1. Laboratory:

• CEA (Carcinoembryonic Antigen): Pre-treatment baseline >5 ng/mL = adverse prognostic factor. Used for monitoring recurrence (rising trend = recurrence until proven otherwise). Not for screening (low sensitivity/specificity).
• CBC, CMP (LFTs, Renal), Coagulation, CEA.
• Germline Genetic Testing: Recommended for all patients <50, or any age with MSI-H/dMMR tumor, strong family history, or personal history of multiple primaries.

Staging Systems

TNM Classification (AJCC 8th Edition / UICC)

Used for anatomic staging post-resection (pathological) or pre-treatment (clinical – cTNM).

Stage Grouping (Simplified)

• Stage 0: Tis, N0, M0
• Stage I: T1-T2, N0, M0
• Stage II: T3-T4, N0, M0 (IIA: T3; IIB: T4a; IIC: T4b)
• Stage III: Any T, N1-N2, M0 (IIIA, IIIB, IIIC based on T/N combo)
• Stage IV: Any T, Any N, M1 (IVA: M1a; IVB: M1b; IVC: M1c)

Clinical vs. Pathological Staging: Rectal cancer uses Clinical Staging (cTNM) via MRI/EUS/CT to decide neoadjuvant therapy. Pathological Staging (ypTNM) after neoadjuvant + surgery determines prognosis and adjuvant therapy need. ypStage** is the most prognostic.

Treatment: A Multidisciplinary Team (MDT) Approach

All rectal cancer cases must be discussed at a Colorectal Cancer MDT Meeting (Surgeon, Radiation Oncologist, Medical Oncologist, Radiologist, Pathologist, Nurse Specialist, Stoma Therapist).

Treatment Algorithm by Risk Stage (cTNM)

1. Very Early / Low Risk (cT1 N0, Good Histology)

• Local Excision (Transanal Endoscopic Microsurgery – TEM / TAMIS): Organ preservation. Indicated for: Well/Mod differentiated, No LVI, No PNI, <3cm, <1/3 circumference, clear margins achievable.
• Risk of Nodal Metastasis in T1: ~8-12% (Higher if Poor Diff, LVI+, PNI+, Deep SM invasion >1000um / SM3, Budding High).
• Completion TME Surgery Required if final pathology shows unfavorable features (Positive margin <1mm, Poor diff, LVI+, PNI+, Deep SM3, High Budding).

2. Early / Intermediate Risk (cT2 N0, or cT1 High Risk, or cT3a/b N0 “Good” MRI)

• Controversy Area.
• Option A: Upfront Surgery (TME) + Adjuvant Chemo (if high risk path features). Avoids radiation toxicity. Risk of positive CRM/Recurrence if MRI understages.
• Option B: Short-Course Radiotherapy (SCRT) 5×5 Gy → Immediate Surgery. “Stockholm” / Polish approach. Reduces local recurrence. No chemo sensitization.
• Option C: Long-Course Chemoradiation (LCCRT) 45-50.4 Gy + 5-FU/Capecitabine → Surgery (6-10 wks later). Standard US historical approach. Higher downstaging rates.
• Current Trend (Organ Preservation): LCCRT or TNT (Total Neoadjuvant Therapy) → Watch & Wait if Clinical Complete Response (cCR).

3. Locally Advanced / High Risk (cT3 c/d, cT4, cN+, EMVI+, MRF+)

• Standard of Care (Current): Total Neoadjuvant Therapy (TNT).
• Sequence 1: Induction Chemo (FOLFOX or CAPOX x 4-6 cycles) → Consolidation Chemoradiation (LCCRT or SCRT) → Surgery.
• Sequence 2: Chemoradiation (LCCRT or SCRT) → Consolidation Chemo (FOLFOX/CAPOX) → Surgery.
• Evidence: RAPIDO, PRODIGE 23, OPRA trials. TNT improves Disease-Free Survival (DFS), Pathologic Complete Response (pCR) rates (25-30%), and Organ Preservation rates. Reduces distant metastases (systemic control).
• Surgery: TME (6-12 weeks post-RT completion).
• Adjuvant Chemo: Post-op chemo duration adjusted based on neoadjuvant received (Total 6 months perioperative chemo standard).

4. Metastatic Disease (Stage IV)

• Oligometastatic (Resectable/Ablatable Liver/Lung Mets): Curative intent possible. TNT → Resection Primary + Mets (Simultaneous or Staged). Systemic therapy backbone: FOLFOX/FOLFIRI + Biologic (Anti-VEGF Bevacizumab or Anti-EGFR Cetuximab/Panitumumab if RAS WT).
• Unresectable / Widespread: Palliative systemic therapy. Goal: Symptom control, life prolongation, quality of life.
• MSI-H/dMMR: First-line Immunotherapy (Pembrolizumab/Nivolumab ± Ipilimumab). High response rates, durable.
• MSS/pMMR (95%): Chemo doublet (FOLFOX/FOLFIRI) + Bevacizumab (1st line standard). RAS WT: Anti-EGFR option (Left-sided primary benefit > Right-sided).
• Later Lines: Regorafenib, TAS-102 (Trifluridine/Tipiracil), Fruquintinib. HER2+: Tucatinib/Trastuzumab. NTRK Fusion: Larotrectinib/Entrectinib. BRAF V600E: Encorafenib + Cetuximab.

5. Organ Preservation Strategies (Non-Operative Management – NOM)

• Goal: Cure without radical surgery (avoid stoma, preserve sphincter/sexual/urinary function).
• Selection: cT2-3 N0-1, favorable biology, Clinical Complete Response (cCR) after TNT/LCCRT.
• cCR Definition: Endoscopy (white scar/ulcer healing, no mass), MRI (mrTRG 1-2, fibrosis only), DRE (no palpable induration), CEA normal.
• Surveillance (Strict Protocol – e.g., Habr-Gama / OPRA): q3mo x 2yrs, q6mo x 3yrs (Endoscopy, MRI, DRE, CEA).
• Salvage Surgery: Immediate TME if local regrowth detected (≈20-30% at 3-5 yrs). Outcomes equivalent to upfront surgery if salvaged early.
• Patient Selection & Shared Decision Making Critical.

Surgical Procedures: Technical Details

Total Mesorectal Excision (TME) – The Gold Standard

• Principle: Sharp dissection in the “Holy Plane” (areolar plane between visceral fascia propria of mesorectum and parietal fascia of pelvic sidewall).
• Autonomic Nerve Preservation: Identification and sparing of:
• Hypogastric Nerves (Sympathetic): Ejaculation (male), bladder neck closure.
• Pelvic Splanchnic Nerves (Parasympathetic S2-S4): Erection, bladder detrusor contraction, rectal motility.
• Inferior Hypogastric Plexus: Integration center.
• Distal Margin: 1 cm distal margin is sufficient for most rectal cancers (previously 2-5cm). For T1/T2, 5mm may suffice. Frozen section if concern.
• Circumferential Resection Margin (CRM): >1 mm is the goal. Positive CRM (≤1mm) = High local recurrence risk, worse survival.

Types of Resection

Minimally Invasive Surgery (MIS)

• Laparoscopic TME: Non-inferior to open for cancer outcomes (COLOR II, COREAN, ACOSOG Z6051 trials). Less pain, faster recovery. Conversion to open if difficult (narrow pelvis, obesity, T4, bleeding).
• Robotic TME (Da Vinci): Superior ergonomics, 3D vision, wristed articulation in narrow pelvis. ROLARR trial: Non-inferior to lap; lower conversion rates in males/obese. Cost higher.
• TaTME (Transanal TME): “Bottom-up” approach. Useful for difficult pelvic anatomy (male, obese, narrow pelvis). Norwegian Morbidity Alert (2019/2020): Higher early local recurrence rates reported in some registries. Currently: Restricted to clinical trials / highly selected centers with strict credentialing/registry.

Management of Complications & Functional Outcomes

1. Anastomotic Leak (AL)

• Incidence: 5–15% (Low/Ultra-low higher).
• Risk Factors: Male, Low anastomosis (<6cm), Neoadjuvant RT, Intraop complications, Smoking, Malnutrition, Steroid use.
• Diagnosis: Clinical (pain, fever, leukocytosis), CT with rectal contrast (extraluminal contrast), Endoscopy.
• Management:
• Asymptomatic/Contained: Antibiotics, drainage (percutaneous), bowel rest.
• Peritonitis/Septic: Re-laparotomy → Washout + Diversion (Ileostomy/Colostomy) +/− Takedown (Hartmann’s).
• Long-term Consequence: Stricture (dilatation), Chronic sinus, Functional impairment (LARS).

2. Low Anterior Resection Syndrome (LARS)

• Definition: Cluster of bowel symptoms after sphincter-saving surgery. Affects 70-90% of patients; Major LARS ~30-40%.
• Symptoms:
• Frequency/Urgency: >7 BMs/day, clustering (multiple BMs in short window).
• Incontinence: Flatus, liquid, solid (passive or urge).
• Emptying Difficulties: Tenesmus, fragmentation, feeling incomplete.
• Pathophysiology: Loss of rectal reservoir (capacitance), Neurectomy (denervation), Sphincter trauma, Altered microbiome, RT fibrosis.
• Management (Stepwise):

1. Diet/Fiber: Soluble fiber (Psyllium) + Loperamide (titrate dose/timing).
2. Pelvic Floor Rehab / Biofeedback: First-line for incontinence/emptying.
3. Transanal Irrigation (TAI / Peristeen): Highly effective for clustering/emptying.
4. Sacral Neuromodulation (SNM): Refractory urgency/incontinence.
5. Surgical: Gracilis interposition, Neosphincter, Stoma (last resort).

• Assessment Tool: LARS Score (5 questions, 0-42). >30 = Major LARS.

3. Sexual & Urinary Dysfunction

• Etiology: Autonomic nerve injury (Sympathetic → Ejaculation/Erection; Parasympathetic → Erection/Lubrication/Bladder emptying).
• Male: Retrograde ejaculation (Sympathetic injury), Erectile Dysfunction (Parasympathetic injury).
• Female: Dyspareunia (vaginal stenosis/fibrosis from RT), Lubrication issues, Orgasm difficulty.
• Urinary: Retention (early), Frequency/Urgency/Incomplete emptying (late).
• Management: PDE5 inhibitors, Vacuum devices, Penile rehab (Male); Dilators, Lubricants, Hormonal therapy (Female); Clean Intermittent Catheterization (CIC), Anticholinergics/Beta-3 agonists (Urinary).

Follow-Up and Survivorship

Aims

1. Detect curable recurrence (Local, Liver, Lung).
2. Detect metachronous neoplasia (New polyps/cancers).
3. Manage late effects (LARS, Neuropathy, Stoma issues, Psychosocial, Cardiac, Bone health).
4. Health promotion (Lifestyle, Vaccination, Screening for other cancers).

Standard Surveillance Schedule (NCCN / ESMO / ASCO Guidelines)

Late Effects Management

• Peripheral Neuropathy (Oxaliplatin): Chronic in 30-50%. Duloxetine, Gabapentin, PT/OT, Acupuncture.
• Bone Health: Aromatase inhibitors (if breast ca history), Steroids, Premature menopause (RT/Chemo) → DEXA scan, Vit D/Calcium, Bisphosphonates/Denosumab.
• Cardiotoxicity: 5-FU (Coronary spasm), Anthracyclines (rare in CRC), Radiation (Late CAD/Valvular). Risk factor modification.
• Psychosocial: Fear of recurrence, Body image (Stoma), Financial toxicity, Fatigue. Referral to Psycho-oncology, Support groups, Stoma nurses.

Special Populations & Clinical Scenarios

1. Young-Onset Rectal Cancer (<50 years)

• Epidemiology: Rising sharply (Birth cohort effect). More advanced stage at dx (delayed diagnosis, no screening). Higher rates of signet ring, mucinous, MSI-H (Lynch), left-sided.
• Unique Challenges: Fertility preservation (Sperm banking, Oocyte/Embryo cryopreservation, Ovarian transposition before pelvic RT), Genetic counseling (High yield), Psychosocial (Parenting, Career, Finance), Sexual function, Long-term survivorship (Secondary malignancies from RT/Chemo).
• Treatment: Same principles, but higher threshold for organ preservation (long life ahead), aggressive fertility counseling mandatory.

2. Rectal Cancer in Pregnancy

• Rare (~1:10,000 pregnancies).
• Diagnosis: Colonoscopy safe in 2nd trimester (sedation minimal). MRI without Gadolinium safe (Gadolinium contraindicated – crosses placenta). CT avoided.
• Management by Trimester:
• 1st Trimester: High teratogenicity risk (Chemo/RT). Delay treatment if early stage (T1-2 N0). If advanced → Termination discussed / Neoadjuvant Chemo (FOLFOX – avoid 5-FU bolus? Actually 5-FU cat D, Oxaliplatin cat D) generally avoided 1st tri. Surgery (TME) possible 2nd tri.
• 2nd Trimester: Safest window for Surgery (TME) + Chemo (FOLFOX/CapeOx – 5-FU/Oxaliplatin Category D but used if benefit > risk). Avoid Radiation.
• 3rd Trimester: Aim for delivery (34-37 wks) → Maternal treatment postpartum. If urgent maternal need → C-section + Surgery simultaneously.
• Multidisciplinary: Maternal-Fetal Med, Neonatology, Ethics.

3. Elderly / Frail Patients (>75-80 years / Frailty)

• Assessment: Comprehensive Geriatric Assessment (CGA) – not just Chronological age. Tools: G8, VES-13, Fried Frailty Phenotype.
• Treatment De-escalation:
• Early Stage: Local excision (TEM) or Contact Brachytherapy (Papillon) +/− External Beam RT (Organ preservation focus).
• Locally Advanced: Short-Course RT (5x5Gy) alone → Surgery (No chemo). Or RT alone (Hypofractionated) for non-surgical candidates (“Watch & Wait” if cCR).
• Adjuvant Chemo: Single-agent Capecitabine or 5-FU/LV (avoid Oxaliplatin neuropathy). 3 months vs 6 months (IDEA collaboration – low risk Stage III: 3mo non-inferior).
• Goal: Maintain independence, QoL, avoid permanent stoma if possible.

4. Local Recurrence (LR)

• Incidence: 5-10% (TME era + Neoadjuvant).
• Workup: MRI Pelvis (Mandatory), PET-CT, Biopsy.
• Curative Intent (Pelvic Exenteration): Only option for cure. Requires R0 resection.
• Anterior: Cystoprostatectomy (M) / Anterior Exenteration (Bladder, Uterus, Vagina, Ovaries – F). Urinary diversion (Ileal Conduit / Neobladder).
• Posterior / Total: Sacrectomy (Partial/Total) + Visceral resection. High morbidity (Flail leg, Neuropathic pain, Wound complications).
• Adjuvant/Neoadjuvant: Re-irradiation (Chemo-RT or SABR/SBRT) + Chemo often used pre-op.
• Palliative: Systemic therapy, Pain management (Celiac/Hypogastric plexus block), Stenting, Diversion.

Prevention and Risk Reduction

Primary Prevention (Lifestyle)

• Diet: Mediterranean diet pattern. Fiber ≥25-30g/day (Whole grains, legumes, veg, fruit). Red meat <500g cooked/week. Avoid Processed Meat. Calcium/Dairy probable protective.
• Physical Activity: 150 min moderate / 75 min vigorous / week.
• Weight: Maintain BMI 18.5–24.9. Avoid central obesity.
• Alcohol: Limit ≤1 drink/day (Women), ≤2 drinks/day (Men). Best: None.
• Smoking: Cessation reduces risk over time (approaches never-smoker ~20 yrs post-quit).
• Aspirin / NSAIDs: USPSTF Grade B Recommendation: Initiate Low-dose Aspirin (81mg) Age 50-59 with ≥10% 10-yr CVD risk and life expectancy ≥10yrs and willing to take 10yrs. Also reduces CRC incidence/mortality (latency ~10yrs). Not recommended for average risk <50 or >70 solely for CRC prevention. Decision individualized (Bleeding risk).

Secondary Prevention (Screening / Surveillance)

• Adherence to Screening Guidelines (Start 45).
• Polypectomy: Complete resection of adenomas/serrated polyps prevents cancer (Adenoma-Carcinoma Sequence / Serrated Pathway).
• Surveillance Compliance: Post-polypectomy and Post-CRC resection colonoscopy intervals.

Chemoprevention (High Risk)

• Lynch Syndrome: Aspirin 600mg/day (CAPP2 trial) → Reduced CRC incidence after 5+ yrs use. Dose optimization ongoing (CAPP3).
• FAP: Sulindac / Celecoxib (Polyp regression), but surgery remains definitive.

Questions to Ask Your Care Team

• Diagnosis/Staging: “What is my exact clinical stage (cTNM) based on MRI? Is my CRM threatened? Do I have EMVI?”
• Molecular: “Has my tumor been tested for MSI/MMR, RAS, BRAF, HER2? Am I a candidate for immunotherapy?”
• Treatment Plan: “Why is this sequence (TNT vs Surgery first) recommended for me? What are the alternatives?”
• Surgery: “What is the probability of a permanent stoma? Will you perform TME? What is your surgeon volume/annual case load?”
• Fertility: (If applicable) “Can I be referred to a fertility specialist before treatment starts?”
• Organ Preservation: “Am I a candidate for ‘Watch & Wait’ if I have a complete response?”
• Side Effects: “What is the plan for managing neuropathy/LARS/sexual dysfunction?”
• Clinical Trials: “Are there any clinical trials I qualify for?”
• Survivorship: “Who coordinates my long-term follow-up? When do I get my survivorship care plan?”

Glossary of Key Terms

References

1. Amin, M.B. et al. (eds.) (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer.
2. Andre, T. et al. (2020) ‘Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer’, New England Journal of Medicine, 383(23), pp. 2207–2218.
3. Appelt, A.L. et al. (2015) ‘High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study’, The Lancet Oncology, 16(8), pp. 919–927.
4. Baba, Y. et al. (2021) ‘Rectal cancer’, The Lancet, 398(10317), pp. 2173–2187.
5. Bahadoer, R.R. et al. (2021) ‘Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy alone in patients with locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial’, The Lancet Oncology, 22(1), pp. 29–42.
6. Benson, A.B. et al. (2023) ‘NCCN Guidelines Insights: Rectal Cancer, Version 6.2023’, Journal of the National Comprehensive Cancer Network, 21(9), pp. 866–875.
7. Bhangu, A. et al. (2022) ‘Transanal total mesorectal excision for rectal cancer: an international, multicentre, prospective cohort study’, The Lancet Oncology, 23(1), pp. 68–78. (Norwegian Morbidity Context).
8. Brenner, H. et al. (2014) ‘Colorectal cancer screening’, The Lancet, 383(9927), pp. 1490–1502.
9. Cancer Genome Atlas Network (2012) ‘Comprehensive molecular characterization of human colon and rectal cancer’, Nature, 487(7407), pp. 330–337.
10. Caplin, S. et al. (2022) ‘ESMO Clinical Practice Guidelines: Rectal Cancer’, Annals of Oncology, 33(10), pp. 951–971.
11. Chau, I. et al. (2022) ‘Neoadjuvant chemotherapy in rectal cancer: the evolving landscape’, Nature Reviews Clinical Oncology, 19(11), pp. 711–725.
12. Connell, L.C. et al. (2019) ‘Low anterior resection syndrome (LARS): a systematic review’, Colorectal Disease, 21(4), pp. 373–385.
13. Dekker, E. et al. (2019) ‘Colorectal cancer’, The Lancet, 394(10207), pp. 1467–1480.
14. Fokas, E. et al. (2019) ‘Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer’, JAMA Oncology, 5(7), pp. 992–1000. (PRODIGE 23).
15. Glynne-Jones, R. et al. (2017) ‘Rectal cancer’, The Lancet, 390(10109), pp. 2277–2290.
16. Guinney, J. et al. (2015) ‘The consensus molecular subtypes of colorectal cancer’, Nature Medicine, 21(11), pp. 1350–1356.
17. Habr-Gama, A. et al. (2014) ‘Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results’, Annals of Surgery, 260(4), pp. 708–713.
18. Hewitson, P. et al. (2008) ‘Screening for colorectal cancer using the faecal occult blood test’, Cochrane Database of Systematic Reviews, (1), Art. No.: CD001216.
19. Hong, T.S. et al. (2020) ‘NCCN Guidelines Insights: Rectal Cancer, Version 2.2020’, Journal of the National Comprehensive Cancer Network, 18(6), pp. 673–683.
20. Iversen, L.H. et al. (2019) ‘Aspects of survival from colorectal cancer in Denmark’, Danish Medical Journal, 66(11).
21. Kahokehr, A. et al. (2021) ‘Management of rectal cancer in young adults’, British Journal of Surgery, 108(10), pp. 1187–1198.
22. Kapiteijn, E. et al. (2001) ‘Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer’, British Journal of Surgery, 88(11), pp. 1519–1526.
23. Kim, M.J. et al. (2020) ‘MRI staging of rectal cancer: a practical guide for radiologists’, Korean Journal of Radiology, 21(5), pp. 547–562.
24. Labianca, R. et al. (2022) ‘Early colon cancer: ESMO Clinical Practice Guidelines’, Annals of Oncology, 33(10), pp. 991–1007. (Context for adjuvant).
25. Lanza, G. et al. (2017) ‘Immunotherapy in microsatellite instability-high colorectal cancer’, Cancer Treatment Reviews, 54, pp. 37–45.
26. Loree, J.M. and Kopetz, S. (2019) ‘Right-sided vs left-sided colon cancer: biology and treatment implications’, Current Oncology Reports, 21(8), p. 68.
27. Maas, M. et al. (2010) ‘MRI after chemoradiotherapy for rectal cancer: a new approach to tumor regression grading’, Radiology, 256(1), pp. 101–110. (mrTRG).
28. McShane, J. et al. (2021) ‘Fertility preservation in young women with rectal cancer’, The Lancet Oncology, 22(1), pp. e1–e2.
29. Nagtegaal, I.D. et al. (2020) ‘The 2019 WHO classification of tumours of the digestive system’, Histopathology, 76(2), pp. 182–188.
30. National Institute for Health and Care Excellence (NICE) (2020) Colorectal cancer: diagnosis and management. NICE Guideline [NG151].
31. O’Neil, B.H. et al. (2018) ‘Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma’, Journal of Clinical Oncology, 36(15), pp. 1465–1472.
32. Park, J.H. et al. (2020) ‘Comparison of robotic versus laparoscopic total mesorectal excision for rectal cancer: a systematic review and meta-analysis’, Annals of Surgical Treatment and Research, 98(5), pp. 239–250.
33. Quirke, P. et al. (2007) ‘Effect of plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial’, The Lancet, 369(9566), pp. 821–828.
34. Renehan, A.G. et al. (2021) ‘Watch-and-wait approach for rectal cancer’, Nature Reviews Clinical Oncology, 18(3), pp. 165–178.
35. Sauer, R. et al. (2004) ‘Preoperative versus postoperative chemoradiotherapy for rectal cancer’, New England Journal of Medicine, 351(17), pp. 1731–1740. (German CAO/ARO/AIO-94).
36. Siegel, R.L. et al. (2023) ‘Colorectal cancer statistics, 2023’, CA: A Cancer Journal for Clinicians, 73(3), pp. 233–254.
37. Smith, J.J. et al. (2019) ‘Nonoperative management of rectal cancer: a practical guide for clinicians’, American Society of Clinical Oncology Educational Book, 39, pp. 549–557.
38. Stintzing, S. et al. (2017) ‘Prognostic and predictive value of primary tumor side in metastatic colorectal cancer’, ESMO Open, 2(2), e000170.
39. The Lancet Oncology Commission (2022) ‘Global cancer surgery: delivering safe, affordable, and timely cancer surgery’, The Lancet Oncology, 23(1), pp. e1–e12.
40. Van Cutsem, E. et al. (2020) ‘ESMO Consensus Guidelines for the management of patients with metastatic colorectal cancer’, Annals of Oncology, 31(10), pp. 1291–1308.
41. Van der Pas, M.H. et al. (2013) ‘Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial’, The Lancet Oncology, 14(3), pp. 210–218.
42. Winawer, S.J. et al. (1993) ‘Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup’, New England Journal of Medicine, 329(27), pp. 1977–1981.
43. You, Y.N. et al. (2020) ‘Organ preservation in rectal cancer: current status and future directions’, Nature Reviews Clinical Oncology, 17(12), pp. 767–782.
44. Zaborowski, A. et al. (2016) ‘Quality of life after rectal cancer treatment’, Journal of Gastrointestinal Oncology, 7(3), pp. 441–451.